NCT06943235RecruitingPhase 2
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve the efficacy? This study aims to explore the efficacy and safety of simultaneous integrated boost hyperfractionation radiotherapy combined with probiotics and Adalberg monoclonal antibody consolidation therapy for small cell lung cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Apr 2025
- Start date
- 25 Apr 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT06943235
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 25 Apr 2025 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history of other malignant tumors and have received chemotherapy in the past 3 years;
- History of chest radiotherapy;
Other
- Progress after 2 induction treatments;
- Severe emphysema, interstitial changes in the lungs, COPD patients;
- Resting blood oxygen\<93;
Who the study is looking for
- Sign written informed consent before implementing any experimental procedures;
- Age range: 18-80 years old;
- Pathological diagnosis of small cell lung cancer;
- Limited stage;
- ECOG PS 0-1；
- Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy;
- Expected survival time\>3 months;
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.